In this context, we sought to assess whether methylation of the MGMT promoter was a predictor of response to TMZ in patients diagnosed with GBM in our hospital; additionally, we wanted to determine whether its predictive value is independent of age, functional status and relevant molecular markers. The gene discussed is MGMT; the disease is glioblastoma.